{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:23:48Z","timestamp":1792700628492,"version":"4.5.0"},"reference-count":29,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018262","name":"Intercept pharmaceuticals","doi-asserted-by":"crossref","award":["Unrestricted grant"],"award-info":[{"award-number":["Unrestricted grant"]}],"id":[{"id":"10.13039\/100018262","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2019,11,16]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The clinical benefit of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) has never been reported in absolute measures. The aim of this study was to assess the number needed to treat (NNT) with UDCA to prevent liver transplantation (LT) or death among patients with PBC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The NNT was calculated based on the untreated LT-free survival and HR of UDCA with respect to LT or death as derived from inverse probability of treatment weighting-adjusted Cox proportional hazard analyses within the Global PBC Study Group database.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 3902 patients with a median follow-up of 7.8 (4.1\u201312.1) years. The overall HR of UDCA was 0.46 (95% CI 0.40 to 0.52) and the 5-year LT-free survival without UDCA was 81% (95% CI 79 to 82). The NNT to prevent one LT or death within 5 years (NNT<jats:sub>5y<\/jats:sub>) was 11 (95% CI 9 to 13). Although the HR of UDCA was similar for patients with and without cirrhosis (0.33 vs 0.31), the NNT<jats:sub>5y<\/jats:sub> was 4 (95% CI 3 to 5) and 20 (95% CI 14 to 34), respectively. Among patients with low alkaline phosphatase (ALP) (\u22642\u00d7 the upper limit of normal (ULN)), intermediate ALP (2\u20134\u00d7 ULN) and high ALP (&gt;4\u00d7 ULN), the NNT<jats:sub>5y<\/jats:sub> to prevent one LT or death was 26 (95% CI 15 to 70), 11 (95% CI 8 to 17) and 5 (95% CI 4 to 8), respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The absolute clinical efficacy of UDCA with respect to LT or death varied with baseline prognostic characteristics, but was high throughout. These findings strongly emphasise the incentive to promptly initiate UDCA treatment in all patients with PBC and may improve patient compliance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/gutjnl-2019-319057","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T17:25:10Z","timestamp":1576517110000},"page":"1502-1509","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":44,"title":["Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis"],"prefix":"10.1136","volume":"69","author":[{"given":"Maren H","family":"Harms","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozanne C","family":"de Veer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem J","family":"Lammers","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Corpechot","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9patologie, Centre de R\u00e9f\u00e9rence des Maladies Inflammatoires des Voies Biliaires, H\u00f4pital Saint-Antoine, APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Thorburn","sequence":"additional","affiliation":[{"name":"The Sheila Sherlock Liver Centre and UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L A","family":"Janssen","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease, Francis Family Liver Clinic, Toronto Western Hospital Liver Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D","family":"Lindor","sequence":"additional","affiliation":[{"name":"College of Health Solutions, Arizona State University, Phoenix, Arizona, USA"},{"name":"Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak J","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Birmingham NIHR Biomedical Research Centre and Centre for Liver Research, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon M","family":"Hirschfield","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease, Francis Family Liver Clinic, Toronto Western Hospital Liver Centre, Toronto, Ontario, Canada"},{"name":"Birmingham NIHR Biomedical Research Centre and Centre for Liver Research, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Pares","sequence":"additional","affiliation":[{"name":"Liver Unit, Hospital Cl\u00ednic, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarosa","family":"Floreani","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, Universita degli Studi di Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlyn J","family":"Mayo","sequence":"additional","affiliation":[{"name":"Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Program for Autoimmune Liver Diseases, International Center for Digestive Health, Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Maria","family":"Battezzati","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Milan, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Nevens","sequence":"additional","affiliation":[{"name":"Department of Hepatology, UZ Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyriel Y","family":"Ponsioen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology - location Academic Medical Center, Amsterdam University Medical Centres, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L","family":"Mason","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris V","family":"Kowdley","sequence":"additional","affiliation":[{"name":"Liver Care Network and Organ Care Research, Swedish Medical Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E","family":"Hansen","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease, Francis Family Liver Clinic, Toronto Western Hospital Liver Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk R van","family":"Buuren","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-0931","authenticated-orcid":false,"given":"Adriaan J","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"key":"2025090714405236000_69.8.1502.1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090714405236000_69.8.1502.2","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"The Lancet"},{"key":"2025090714405236000_69.8.1502.3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study","volume":"65","author":"Trivedi","year":"2016","journal-title":"Gut"},{"key":"2025090714405236000_69.8.1502.4","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"key":"2025090714405236000_69.8.1502.5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/hepr.12270","article-title":"Working subgroup for clinical practice guidelines for primary biliary C. guidelines for the management of primary biliary cirrhosis: the intractable hepatobiliary disease Study Group supported by the Ministry of health, labour and welfare of Japan","volume":"44","year":"2014","journal-title":"Hepatol Res"},{"key":"2025090714405236000_69.8.1502.6","first-page":"394","article-title":"Practice guidance from the American association for the study of liver diseases","volume":"2019","author":"Lindor","year":"2018","journal-title":"Hepatology"},{"key":"2025090714405236000_69.8.1502.7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J Hepatol"},{"key":"2025090714405236000_69.8.1502.8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J Hepatol"},{"key":"2025090714405236000_69.8.1502.9","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/S0618-8278(19)30807-2","article-title":"FRI-057-A review of primary biliary cholangitis practice in Wales: time for specialist care","volume":"70","author":"Haboubi","year":"2019","journal-title":"J Hepatol"},{"key":"2025090714405236000_69.8.1502.10","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2017.12.033","article-title":"Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment","volume":"16","author":"Lu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090714405236000_69.8.1502.11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouill\u00e8res","year":"1998","journal-title":"Hepatology"},{"key":"2025090714405236000_69.8.1502.12","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"2025090714405236000_69.8.1502.13","unstructured":"Lanehart RE , Rodriguez de Gil P , Sook Kim E , et al . Propensity score analysis and assessment of propensity score approaches using SAS\u00ae procedures. SAS Global Forum 2012:5\u20136."},{"key":"2025090714405236000_69.8.1502.14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"2025090714405236000_69.8.1502.15","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"2025090714405236000_69.8.1502.16","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ"},{"key":"2025090714405236000_69.8.1502.17","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"2025090714405236000_69.8.1502.18","unstructured":"Kremers WK . Concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time. Department of Health Sciences Research and The William J. von Liebig Transplant Center Mayo Clinic, 2007."},{"key":"2025090714405236000_69.8.1502.19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.0006-341X.2005.030814.x","article-title":"Survival model predictive accuracy and ROC curves","volume":"61","author":"Heagerty","year":"2005","journal-title":"Biometrics"},{"key":"2025090714405236000_69.8.1502.20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"key":"2025090714405236000_69.8.1502.21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"2025090714405236000_69.8.1502.22","doi-asserted-by":"crossref","first-page":"916","DOI":"10.7326\/0003-4819-117-11-916","article-title":"Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness?","volume":"117","author":"Naylor","year":"1992","journal-title":"Ann Intern Med"},{"key":"2025090714405236000_69.8.1502.23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1177\/0272989X14526641","article-title":"Confusing relative risk with absolute risk is associated with more Enthusiastic beliefs about the value of cancer screening","volume":"34","author":"Caverly","year":"2014","journal-title":"Med Decis Making"},{"key":"2025090714405236000_69.8.1502.24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/bmj.309.6957.761","article-title":"Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration","volume":"309","author":"Bucher","year":"1994","journal-title":"BMJ"},{"key":"2025090714405236000_69.8.1502.25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"key":"2025090714405236000_69.8.1502.26","doi-asserted-by":"crossref","unstructured":"Saffioti F , Gurusamy KS , Eusebi LH , et al . Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;28.doi:10.1002\/14651858.CD011648","DOI":"10.1002\/14651858.CD011648.pub2"},{"key":"2025090714405236000_69.8.1502.27","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"330","author":"Poupon","year":"1994","journal-title":"N Engl J Med"},{"key":"2025090714405236000_69.8.1502.28","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.arcmed.2006.08.005","article-title":"Liver biopsy assessment in chronic hepatitis","volume":"38","author":"Lefkowitch","year":"2007","journal-title":"Arch Med Res"},{"key":"2025090714405236000_69.8.1502.29","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/j.1572-0241.2006.00699.x","article-title":"Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients","volume":"101","author":"ter Borg","year":"2006","journal-title":"Am J Gastroenterol"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2019-319057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T21:42:08Z","timestamp":1757281328000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2019-319057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,16]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,7,7]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/gutjnl-2019-319057"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2019-319057","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,16]]}}}